262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study.
Saved in:
| Title: | 262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study. |
|---|---|
| Authors: | Bridgewater, J.A.1 (AUTHOR), Gardini, A. Casadei2 (AUTHOR), Wilmink, H.3 (AUTHOR), Mercade, T. Macarulla4 (AUTHOR), Sim, H-W.5 (AUTHOR), Verslype, C.6 (AUTHOR), Roderburg, C.7 (AUTHOR), Touchefeu, Y.8 (AUTHOR), McDermott, R.S.9 (AUTHOR), Kordes, M.10 (AUTHOR), Lee, C-K.11 (AUTHOR), Vogel, A.12 (AUTHOR), Kzhdryan, H.G.K.13 (AUTHOR), Vidra, R.A.14 (AUTHOR), Rumpold, H.15 (AUTHOR), Sullivan, A.16 (AUTHOR), Gharbi, H.17 (AUTHOR), Minguez, V. Manuel17 (AUTHOR), Robert, R.17 (AUTHOR), Rimassa, L.18 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 1, Vol. 36, pS103-S103. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.05.277 |
